In ELISpot assays for the frequencies of LAA epitope-specific T cells, the responses were higher in CML patients compared to the healthy controls, dominated by HLA-I peptides from the pLAAs, and P187-WT1 and hTERT from eLAAs (Fig. 3). Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.